CAR-T细胞疗法：当前局限与潜在策略
CAR-T cell therapy: current limitations and potential strategies
嵌合抗原受体（CAR）T细胞疗法已成为癌症治疗的新支柱，在部分B细胞白血病和淋巴瘤中产生显著疗效，但在实体瘤和部分血液肿瘤中仍受多重限制。主要障碍包括危及生命的严重毒性、抗肿瘤活性有限、抗原逃逸（肿瘤不再表达靶点）、细胞难以迁移和浸润肿瘤，以及宿主与肿瘤微环境对CAR-T功能的影响；此外，开发和实施这类治疗需要复杂的人力体系。本文综述了近期通过工程改造提升CAR-T疗效、降低毒性的创新策略，以及克服上述局限的方向。属于领域综述，不提供新的临床数据。
为什么推荐给您：领域综述，无新数据，仅归纳既有障碍与改造策略。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.